ClinicalTrials.gg
CompletedNCT01208012Updated Mar 15, 2011

Impact of Liraglutide on Endothelial Function and Microvascular Blood Flow in Type 2 Diabetes Mellitus

A Phase 4 interventional study of Victoza® in Diabetes Mellitus, Type 2, sponsored by ikfe-CRO GmbH. Completed at 1 site in Germany. Open to participants aged 30 Years to 65 Years. Per ClinicalTrials.gov, last updated 2011-03-15.

Sponsored by ikfe-CRO GmbH · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
30 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 151 studies testing liraglutide in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 1 of them phase 3. Liraglutide · Diabetes Mellitus, Type 2.

Enrollment
93rd of 151
44 · median 62
Started
2010
with 1 other
Phase 4
48 of 151
1 open now
Registered
22nd of 151
by date

Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, this one is the 93rd largest by enrollment, is one of 2 that started in 2010, is one of 48 in phase 4, and was the 22nd registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 151 studies testing liraglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About liraglutide

Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 30 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 151 studies testing liraglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The trial is a phase IV clinical trial investigating the impact of Liraglutide on endothelial function and microvascular blood flow in 44 patients with type 2 diabetes mellitus aged 30-65 and HbA1c ranging from ≥ 5.5% ≤ 7.0%. The patients will be randomized into two study arms, one arm will be treated with Metformin monotherapy, the second arm will be treated with Metformin and Liraglutide at an increasing dose (0.6 mg/day to 1.8 mg/day.)

Read the detailed description

Type 2 Diabetes Mellitus (DM) is associated with increased cardiovascular risk and the majority of type 2 diabetic patients die due to the vascular complications of Diabetes Mellitus. In type 2 diabetic patients, an early marker in the biogenesis of atherosclerosis and cardiovascular disease is the occurrence of endothelial dysfunction with subsequent deterioration in micro- and macrovascular blood flow and tissue supply. Also several mechanistic pathways linking Diabetes Mellitus with endothelial dysfunction and cardiovascular complications are postulated. Recent studies aimed to investigate the vasoprotective effect of strict glycaemic control using conventional treatment algorithms failed to reduce cardiovascular risk in patients with Diabetes Mellitus type 2. Numerous pharmacological drugs are available to reduce blood glucose levels in type 2 diabetic patients. Beside comparable glucose lowering efficacy, some of them evolve limited or even adverse effects on vascular function and cardiovascular risk. Therefore, ideally new treatments in Diabetes Mellitus type 2 provide more than just reducing blood glucose values. Future treatments in type 2 Diabetes Mellitus will be judged on their potency to affect the cardiovascular risk profile in patients with Diabetes Mellitus type 2.

Liraglutide is a Glucagon-like peptide-1 (GLP-1) analogue shown to be effective in the treatment of type 2 Diabetes Mellitus. Liraglutide was shown to improve blood glucose levels not only by stimulating insulin secretion from the β cell, but also by improving the conversion of intact proinsulin into insulin and C-peptide in the granula of the β cell. While in rodents, GLP-1 and its analogues showed an increase in β cell regeneration and an inhibitory effect on β cell apoptosis, the effect of GLP-1 analogues on β cell mass in humans is less clear. Beyond its effects on β cells, Liraglutide and other GLP1 analogues were shown to suppress the glucagon release from α cells and to evolve a supportive effect on weight reduction by central and probably peripheral effects.

Beside these effects of GLP-1-analogues on β cell physiology and glucose metabolism, recent studies suggested several pleiotrophic effects of GLP-1 treatment which go beyond glycaemic control. Receptors for GLP-1 have been located in myocardial and endothelial cells, and GLP-1 supplementation was found to improve myocardial and endothelial function in diabetic and in non-diabetic subjects. In endothelial cells, isolated from human coronary arteries, GLP-1 rapidly activates endothelial nitric oxide synthase (eNOS) and stimulates nitric oxide (NO) production, promotes cell proliferation and inhibits glucolipoapoptosis. In addition, in transformed vascular endothelial cells, GLP-1 protects endothelial dysfunction incurred by tumor necrosis factor-α (TNF-α) through the modulation of the expression of vascular adhesion molecules and plasminogen activator inhibitor-1 (PAI-1). Chronic administration of GLP-1 analogues is associated with a significant reduction in blood pressure. Therefore it seems conceivable, that in patients with Diabetes Mellitus type 2, treatment with the GLP-1 analog Liraglutide might improve the cardiovascular risk profile beyond glucose control by stimulating endothelial NO release and by improving endothelial function.

The goal of our study is to investigate the vascular and endothelial effects of adding Liraglutide treatment to type 2 diabetic patients previously treated with Metformin.

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • Diabetes Mellitus treatment Metformin
04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diabetes Mellitus type 2
  2. ≥ 5.5% and ≤ 7.0%
  3. Treatment with Metformin (daily dose 500 - 3000 mg monotherapy, the past 3 months)
  4. Age 30 - 65 years

Exclusion criteria

Exclusion Criteria:

  1. Pre-treatment with PPAR gamma agonists or DPP IV inhibitors or GLP-1 analogues within the last three months
  2. History of type 1 Diabetes Mellitus
  3. No full legal mental and physical ability to give
  4. Uncontrolled hypertension (systolic blood pressure > 160 mmHg and/or diastolic blood pressure > 90 mmHg)
  5. Anamnestic acute and chronic infections
  6. Inflammatory bowel disease and/or diabetic gastroparesis
  7. Anamnestic history of epilepsy
  8. Anamnestic history of to the study drugs or to drugs with similar chemical structures
  9. History of severe or multiple allergies
  10. Treatment with any other drug within 3 months before trial entry
  11. Progressive fatal disease
  12. History of drug or alcohol abuse in the past 2 years
  13. Liver disease with ASAT or ALAT above 3 times the upper normal limit
  14. Serum potassium > 5.5 mmol/L
  15. Moderate to Severe Kidney disease with a ≤ 60 ml/min
  16. Pregnancy or breast feeding
  17. Sexually active woman of not practicing a highly effective method of as defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, hormonal IUDs, sexual abstinence or vasectomised partner
  18. Have had more than one unexplained episode of severe hypoglycaemia (defined as requiring assistance of another person due to disabling hypoglycaemia) within 6 months prior to screening visit
  19. History of dehydration, diabetic precoma, diabetic ketoacidosis or diabetic gastroparesis
  20. Acute (within the previous 2 days) or scheduled investigation with iodine containing radiopaque material
  21. Acute myocardial infarction, open heart surgery or cerebral event (stroke/) within the previous 6 months
  22. Anamnestic uncontrolled unstable angina pectoris, pericarditis, myocarditis, endocarditis, haemodynamic relevant aortic stenosis, aortic aneurysma or heart insufficiency III or IV
  23. Anamnestic recent pulmonary embolism or pulmonary insufficiency
  24. Smoking within the last 6 months (> 1 cigarette/day)
  25. Planned change in antidiabetic, lipid lowering or blood pressure medication
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • No intervention
    Metformin

    Patients taking Metformin at individual dose

  • Experimental
    Metformin and Liraglutide

    Patients taking Metformin at individual dose and Liraglutide 0.6 mg once daily for the 1st week, 1.2 mg daily for another 5 weeks, 1.8 mg daily for another 6 weeks.

    Drug: Victoza®

Interventions

  • DrugLiraglutideStudies of LiraglutideLiraglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients taking Metformin at individual dose and Liraglutide 0.6 mg once daily for the 1st week, 1.2 mg daily for another 5 weeks, 1.8 mg daily for another 6 weeks. When arrived at the dosage of 1.8 mg daily and the dose is not tolerated by the patient, the dose of Liraglutide can be decreased.Liraglutide is injected in the subcutaneous tissue once daily

    Also known as: Victoza®, Liraglutide

06

What researchers measure

Primary outcomes

  1. The difference in increase of retinal blood flow after flicker stimulation of retinal endothelial cells

    Retinal capillary blood flow will be assessed using scanner laser doppler flowmetry.

    Time frame: timepoint 0 and after 6 and 12 weeks

Secondary outcomes

  1. Central vascular elasticity

    Central arterial elasticity will be measured by Pulse wave velocity.

    Time frame: timepoint 0 and after 6 and 12 weeks

  2. Skin endothelial function and Skin oxygenation

    Microvascular skin blood flow and postcapillary tissue oxygenation (sO2)will be measured.

    Time frame: timepoint 0 and after 6 and 12 weeks

  3. Blood glucose control

    Fasting plasma glucose will be measured.

    Time frame: timepoint 0 and after 6 and 12 weeks

  4. Blood glucose control

    HbA1c will be maesured.

    Time frame: up to 2 weeks before baseline and after 6 and 12 weeks after baseline

  5. Change of biomarkers of sub-clinical inflammation and cardiovascular risk

    Biomarkers PAI-1, hsCRP, VCAM, E-selectin and ADMA will be measured.

    Time frame: timepoint 0 and after 6 and 12 weeks

  6. Change of biomarker of heart failure

    NT-pro BNP will be measured.

    Time frame: timepoint 0 and after 6 and 12 weeks

  7. Insulin/ intact Proinsulin ratio, C-peptide

    Insulin Intact Proinsulin and C-peptide will be maesured.

    Time frame: timepoint 0 and after 6 and 12 weeks

  8. Change of body weight

    Body weight will be measured.

    Time frame: up to 2 weeks before baseline and after 6 and 12 weeks after baseline

  9. Safety evaluation

    The safety evaluation includes: * Metabolic parameters indicating hepatic function (ALAT, ASAT, γ-GT) * Blood analysis (Alkaline Phosphatase, Blood cell count) * Change in pancreas function (Amylase, Lipase) * Change in renal function (Creatinine, Potassium) * Change in thyroid function (Calcitonin) * Vital signs (Blood Pressure, Radial Pulse, ECG) * β-HCG (only female patients of childbearing potential) * Adverse Events * Adverse Drug Reactions

    Time frame: up to 2 weeks before baseline and after 12 weeks post baseline

07

Study locations

1 site
  • IKFE Institute for Clinical Research and Development
    Mainz, 55116, Germany
08

References and documents

Publications

  • Forst T, Michelson G, Ratter F, Weber MM, Anders S, Mitry M, Wilhelm B, Pfutzner A. Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function. Diabet Med. 2012 Sep;29(9):1115-8. doi: 10.1111/j.1464-5491.2012.03589.x. PubMed 22288732 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2010, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2010
First posted
Sep 23, 2010
Start
Apr 2010
Primary completionActual
Nov 2010
CompletionActual
Nov 2010
Last update
Mar 15, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01208012
Lead sponsor
ikfe-CRO GmbH
Collaborators
Novo Nordisk A/S, IKFE Institute for Clinical Research and Development
First posted
Sep 23, 2010
Start date
Apr 2010
Primary completion
Nov 2010
Completion
Nov 2010
Last update
Mar 15, 2011

Study contacts

Thomas Forst, Prof. Dr.
principal investigator · Ikfe GmbH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liraglutide

Start the discussion